Adding Pluvicto to standard therapy in metastatic patients led to a radiographic PFS benefit, but questions remain about ...

A new drug combination cuts the risk of death in people with advanced prostate cancer by 40% over eight years, according to ...

Scientists uncover a molecular weakness that could transform prostate cancer therapy. An international team of researchers has identified a new weakness in prostate cancer cells that could enhance ...

Men with recurrent prostate cancer following surgery or radiation therapy may now have a new chance to live longer. A massive ...

A UCLA study shows that a new treatment combining a radioactive drug with radiation therapy could help delay hormone therapy ...

Prostate cancer is the most common form of cancer in the UK, according to Prostate Cancer UK. Cancer Research UK says ...

Prostate cancer is one of the most common and serious health issues affecting men worldwide. In its early stages, the ...

Metformin failed to prevent metabolic syndrome in men on hormonal therapy for prostate cancer but did improve risk factors ...

Prostate cancer is among the most common types of cancer found in men. It develops in the prostate gland, a small organ ...

Capivasertib addition to standard therapy extended rPFS by 7.5 months in PTEN-deficient metastatic hormone-sensitive prostate ...

Researchers found that patients who took statins alongside apalutamide and standard hormone therapy had higher three-year ...

Prostate cancer is the most common cancer among men after skin cancer, with approximately 1 in 8 men diagnosed in their ...